Description
Key facts
Cell type:HeLa,
Species or organism:Human,
Tissue:Cervix,
Knockout validation:Sanger Sequencing,Western blot,
Mutation description:Knockout achieved by using CRISPR/Cas9, Homozygous: 1 bp deletion in exon 1.,
Disease:Adenocarcinoma
Product details:
Knockout cell lysate achieved by CRISPR/Cas9.
REACH authorisation
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.
Lysate preparation:
Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10).
This means that the protein of interest is denatured.
If you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.
User storage instructions:
Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.
This product is subject to limited use licenses from The Broad Institute and ERS Genomics Limited, and is developed with patented technology. For full details of the limited use licenses and relevant patents please refer to our
limited use license
patent pages
Properties and Storage Information:
Gene name-PSMB10, Gene editing type-Knockout, Gene editing method-CRISPR technology, Knockout validation-Sanger Sequencing, Western blot, Zygosity-Homozygous, Shipped at conditions-Ambient - Can Ship with Ice, Appropriate short-term storage conditions--20°C, Appropriate long-term storage conditions--20°C
Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
PSMB10 also known as MECL1 is a proteasome component involved in protein degradation. This protein has a molecular mass of approximately 29 kDa. PSMB10 is expressed in various tissues with notable expression in the immune system. As a beta subunit of the 20S proteasome MECL1 has a role in cleaving peptides at specific sites contributing to the breakdown of ubiquitinated proteins.
Biological function summary
PSMB10/MECL1 plays a significant role in immune responses. It forms part of the immunoproteasome a variant of the proteasome complex which enhances the generation of antigenic peptides presented on MHC class I molecules. This function is essential for effective immune surveillance and initializing adaptive immunity. In particular PSMB10's influence on antigen processing positions it as an important player in modulating immune system activity.
Pathways
PSMB10/MECL1 participates in pathways associated with protein catabolism and immune signaling. It is involved in the ubiquitin-proteasome pathway which is critical for maintaining cellular protein balance. The function of PSMB10 within the immunoproteasome links it to immune signaling pathways. It has associations with other 20S proteasome subunits such as PSMB8 and PSMB9 which also contribute to the formation of the immunoproteasome complex.
PSMB10/MECL1 has connections to autoimmune diseases and cancer. In autoimmune diseases the altered function of PSMB10 within the immunoproteasome can lead to improper antigen presentation potentially triggering excessive immune responses. In oncology aberrant expression of immunoproteasome subunits including PSMB10 has implications in tumor immune evasion. The interplay with proteins like PSMB9 in these contexts suggests an intricate network affecting disease progression and immune regulation.
